



## SUVEN PHARMACEUTICALS LTD

Regd. Off: 3rd Floor ,SDE Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

### STATEMENT OF UN-AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June, 2020

Sl. No.	PARTICULARS	STANDALONE			
		For the Quarter Ended			For the year ended
		30/06/2020	31/03/2020	30/06/2019	31/03/2020
		Un-Audited	Audited	Un-Audited	Audited
		(1)	(2)	(3)	(4)**
<b>1</b>	<b>Income</b>				
	Revenue from operations	23,823.24	18,476.45	19,739.14	83,378.97
	Other Income	573.91	534.00	244.46	1,811.73
	<b>Total income</b>	<b>24,397.15</b>	<b>19,010.45</b>	<b>19,983.60</b>	<b>85,190.70</b>
<b>2</b>	<b>Expenses</b>				
	a) Cost of materials consumed	6,600.27	6,424.21	5,866.31	24,024.35
	b) Purchases of stock-in-trade	-	-	-	
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	474.64	(1,127.24)	(1,732.14)	(1,105.44)
	d) Employee benefits expense	1,744.42	1,737.70	1,704.87	6,510.44
	e) R & D expenses	307.85	323.03	273.78	1,413.14
	f) Finance costs	320.62	720.37	344.22	2,181.26
	g) Depreciation and amortisation expenses	706.34	696.39	549.73	2,350.69
	h) Manufacturing Expenses	2,388.71	2,538.09	2,495.10	10,384.42
	i) Other Expenses	1,096.61	853.93	884.38	3,672.81
	<b>Total expenses</b>	<b>13,639.46</b>	<b>12,166.48</b>	<b>10,386.25</b>	<b>49,431.67</b>
<b>3</b>	<b>Profit before exceptional items &amp; Tax (1-2)</b>	<b>10,757.69</b>	<b>6,843.97</b>	<b>9,597.35</b>	<b>35,759.03</b>
<b>4</b>	Exceptional Items	-	-		-
<b>5</b>	<b>Profit before Tax (3-4)</b>	<b>10,757.69</b>	<b>6,843.97</b>	<b>9,597.35</b>	<b>35,759.03</b>
<b>6</b>	Tax Expenses			-	
	a) Current tax	2,728.72	1,349.07	2,429.42	8,880.94
	b) Deferred tax	(94.03)	170.83	(324.59)	(129.93)
<b>7</b>	<b>Net Profit/ (Loss) for the period/year(5-6)</b>	<b>8,123.00</b>	<b>5,324.07</b>	<b>7,492.52</b>	<b>27,008.02</b>
<b>8</b>	<b>Other Comprehensive Income</b>			-	
<b>8.a</b>	<b>(i) Items that will not be reclassified to profit or loss</b>	<b>(27.33)</b>	<b>(18.50)</b>	<b>(4.23)</b>	<b>(109.31)</b>
	(ii) Income tax relating to items that will not be reclassified to profit or loss	6.88	4.65	1.48	27.51
<b>8.b</b>	<b>(i) Items that will be reclassified to profit or loss</b>	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>(20.45)</b>	<b>(13.85)</b>	<b>(2.75)</b>	<b>(81.80)</b>
<b>9</b>	<b>Total Comprehensive Income for the period (7+8)</b>	<b>8,102.55</b>	<b>5,310.22</b>	<b>7,489.77</b>	<b>26,926.22</b>
<b>10</b>	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00
<b>11</b>	Other Equity	-	-	-	77,010.16
<b>12</b>	<b>Earning Per Share (EPS) (Face value of Rs.1/- each) :</b>				
	a) Basic	6.38	4.18	5.89	21.22
	b) Diluted	6.38	4.18	5.89	21.22
		(not annualised)	(not annualised)	(not annualised)	

Sl. No.	PARTICULARS	CONSOLIDATED			
		For the Quarter Ended			For the year ended
		30/06/2020	31/03/2020	30/06/2019	31/03/2020
		Un-Audited	Audited	Un-Audited	Audited
	(1)	(2)	(3)	(4)**	
<b>1</b>	<b>Income</b>				
	Revenue from operations	23,823.24	18,476.45	19,739.14	83,378.97
	Other Income	573.91	534.00	244.46	1,811.73
	<b>Total income</b>	<b>24,397.15</b>	<b>19,010.45</b>	<b>19,983.60</b>	<b>85,190.70</b>
<b>2</b>	<b>Expenses</b>				
	a) Cost of materials consumed	6,600.27	6,424.21	5,866.31	24,024.35
	b) Purchases of stock-in-trade	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	474.64	(1,127.25)	(1,732.14)	(1,105.45)
	d) Employee benefits expense	1,744.42	1,737.70	1,704.87	6,510.44
	e) R & D expenses	307.85	323.03	273.78	1,413.15
	e) Finance costs	320.62	721.75	381.90	2,306.60
	f) Depreciation and amortisation expense	706.34	696.40	549.73	2,350.69
	g) Manufacturing Expenses	2,388.71	2,538.09	2,495.10	10,384.42
	h) Other Expenses	1,099.21	855.27	885.42	3,676.58
	<b>Total expenses</b>	<b>13,642.06</b>	<b>12,169.20</b>	<b>10,424.97</b>	<b>49,560.78</b>
<b>3</b>	<b>Profit before exceptional items , Tax &amp; share in profit/(Loss) of Associates (1-2)</b>	<b>10,755.09</b>	<b>6,841.25</b>	<b>9,558.63</b>	<b>35,629.92</b>
<b>4</b>	<b>Add : Share of profit/(Loss) of Associates</b>	<b>1,031.76</b>	<b>2,096.88</b>	<b>1,736.61</b>	<b>4,821.26</b>
<b>5</b>	<b>Profit before exceptional items, Tax (3+4)</b>	<b>11,786.85</b>	<b>8,938.13</b>	<b>11,295.24</b>	<b>40,451.18</b>
<b>6</b>	Exceptional Items	-	-	-	-
<b>7</b>	<b>Profit before Tax (5-6)</b>	<b>11,786.85</b>	<b>8,938.13</b>	<b>11,295.24</b>	<b>40,451.18</b>
<b>8</b>	<b>Tax Expenses</b>				
	a) Current tax	2,728.72	1,349.07	2,429.42	8,880.94
	b) Deferred tax	(94.03)	170.83	(324.60)	(129.93)
<b>9</b>	<b>Net Profit/ (Loss) for the period/year(7-8)</b>	<b>9,152.16</b>	<b>7,418.23</b>	<b>9,190.42</b>	<b>31,700.17</b>
<b>10</b>	<b>Other Comprehensive Income</b>				
<b>10.a</b>	<b>(i) Items that will not be reclassified to profit or loss</b>	<b>(27.33)</b>	<b>(18.49)</b>	<b>(4.23)</b>	<b>(109.30)</b>
	<b>(ii) Income tax relating to items that will not be reclassified to profit or loss</b>	<b>6.88</b>	<b>4.65</b>	<b>1.48</b>	<b>27.51</b>
<b>10.b</b>	<b>(i) Items that will be reclassified to profit or loss</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
	<b>(ii) Income tax relating to items that will be reclassified to profit or loss</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
	<b>Total other Comprehensive Income</b>	<b>(20.45)</b>	<b>(13.84)</b>	<b>(2.75)</b>	<b>(81.79)</b>
<b>11</b>	<b>Total Comprehensive Income for the period (9 + 10)</b>	<b>9,131.71</b>	<b>7,404.39</b>	<b>9,187.67</b>	<b>31,618.38</b>
<b>12</b>	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00
<b>13</b>	Other Equity	-	-	-	83,203.45
<b>14</b>	<b>Earning Per Share (EPS) (Face value of Rs.1/- each) :</b>				
	a) Basic	7.19	5.83	7.22	24.91
	b) Diluted	7.19	5.83	7.22	24.91
		(not annualised)	(not annualised)	(not annualised)	

**Notes** **1)** The above unaudited financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 17, 2020. The above results have been subjected to limited review by the statutory auditors of the company

**2)** The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.

**3)** The consolidated financial results include the results of the wholly owned subsidiary Suven Pharma Inc., and Associate Rising Pharma Holdings Inc.,

**4)** The Board of Directors considered and recommended the issue of bonus shares in the ratio of 1:1, subject to approval of the members in the ensuing annual general meeting.

**5)** The Board announced Employee Stock Option Plan (ESOP) 2020, subject to approval of members in the ensuing annual general meeting of the company.

**6)** The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

**7)\*\*** Consequent to the demerger of Contract Research and Manufacturing services (CRAMS) Undertaking of the erstwhile Suven Life Sciences Limited as a going concern into the Company, pursuant to the Scheme effective from appointed date being 1st October, 2018, the financial results for the year ended 31st March, 2020 are not comparable to that extent with the previous corresponding period.

**8)** The Suven Life Sciences Limited (SLSL/Demergered Company) has to transfer the statutory and regulatory licenses with in India and Outside India so as to enable the Company (SPL) to carry on the business in its name. The process of obtaining the approvals from all departments is a lengthy process. In order to maintain the continuity of the business during these statutory approvals period, the SLSL is continuing the CRAMS business in its own name on behalf of SPL. However, all such operations were recorded in the books of SPL, the same may be continued till the migration of all licenses in the name of SPL.

**9)** The COVID-19 impact on the business and going concern assumption of the company and its subsidiary: On 30 Jan 2020, the World Health Organization (WHO) declared the coronavirus (COVID-19) outbreak a "Public Health Emergency of International Concern" and on 11 Mar 2020, declared it to be pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, quarantines in certain areas and forced closure for certain types of public places and businesses. The actions taken to mitigate the spread expected to continue for more time and may have adverse impact on economics in different geographies in which your Company operates. It is unknown for how long the adverse conditions associated with COVID-19 will last. To date, the Company has not experienced any major consequences or loss of business which will materially impact the financial conditions of the Company.

**10)** Pursuant to a fire accident on April 26, 2020 at Jeedimetla Plant, certain fixed assets and other contents in buildings was damaged. The company has lodged an initial estimate of loss with insurance company and survey is currently ongoing. During the quarter ended June 30, 2020, the company has written off net book value of assets aggregating Rs 109.30 Lakhs and recognised a minimum insurance claim receivable for equivalent amount .

**11)** The figures for the quarter ended March 31, 2020 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to third quarter of the financial year ended March 31 , 2020

**12)** The corresponding previous period figures have been regrouped / reclassified where ever necessary.

**For SUVEN PHARMACEUTICALS LTD**

Place : Hyderabad  
Date : 17th August 2020

**VENKAT JASTI**  
Chairman & MD  
DIN: 00278028